研究目的
To review recent advances and applications of plasmonic and nanoplasmonic biosensors for biomarker diagnosis in clinical practice, focusing on cancer, cardiovascular, and neurodegenerative diseases.
研究成果
The review concludes that nanoplasmonic biosensors have made significant progress in clinical biomarker detection, offering advantages in sensitivity, specificity, and multiplexing. However, challenges remain in device miniaturization, automation, and clinical validation. Future research should focus on integrating these biosensors into POC platforms for widespread clinical use.
研究不足
The review highlights the challenges in miniaturization, automation, and integration of microfluidics for POC devices. It also notes the need for validation of multiplexed detection formats and the gap between laboratory research and clinical application.
1:Experimental Design and Method Selection:
The review discusses the use of plasmonic biosensors, including SPR and LSPR, for biomarker detection. It covers the design of nanostructured surfaces and chemical functionalization strategies for bioreceptor incorporation.
2:Sample Selection and Data Sources:
The review analyzes publications from the past decade on nanoplasmonic biosensors, focusing on clinical applications for biomarker detection.
3:List of Experimental Equipment and Materials:
Includes SPR and LSPR biosensors, gold and silver nanoparticles, and various nanostructured surfaces for biosensing.
4:Experimental Procedures and Operational Workflow:
Describes the functionalization of sensor surfaces with bioreceptors, detection of biomarkers in body fluids, and signal readout methods.
5:Data Analysis Methods:
Discusses the analysis of SPR and LSPR signals for biomarker quantification and the comparison of biosensor performance with conventional methods.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容